Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trialFrederick L Altice
Yale University AIDS Program, Yale University, New Haven, CT 06510 2283, USA
Clin Infect Dis 45:770-8. 2007
..Directly administered antiretroviral therapy (DAART) is one approach to improve treatment adherence among human immunodeficiency virus (HIV)-infected drug users...
- Adherence to hepatitis B virus vaccination at syringe exchange sites
Frederick L Altice
Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
J Urban Health 82:151-61. 2005
..Trust engendered by and mutual respect afforded by such programs result in repeated encounters by active IDUs over time...
- Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy
Duncan Smith Rohrberg Maru
Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
AIDS Behav 12:284-93. 2008
..The presence of depression and the lack of willingness to travel greater than four blocks to receive DAART predicted time-to-discontinuation...
- Antiretroviral treatment regimen outcomes among HIV-infected prisoners
Sandra A Springer
Yale University AIDS Program, New Haven, CT 06510 2283, USA
HIV Clin Trials 8:205-12. 2007
..Despite the high prevalence of HIV in correctional settings, the duration of therapy and response to various highly active antiretroviral therapy (HAART) regimens in this setting is unknown...
Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavirRobert Douglas Bruce
Department of Medicine, Yale University AIDS Program, New Haven, CT, USA
J Acquir Immune Defic Syndr 54:511-4. 2010
..This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX...
- Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market
R Douglas Bruce
Yale University AIDS Program, New Haven, Connecticut, USA
Am J Drug Alcohol Abuse 35:68-72. 2009
..To address this concern, co-formulation of buprenorphine/naloxone (BPN/NLX) replaced buprenorphine alone in Malaysia in December 2006...
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugsFrederick L Altice
Department of Medicine, Section of Infectious Diseases, Yale University, New Haven, CT 06510 2283, USA
Lancet 376:367-87. 2010
..Multifaceted, interdisciplinary approaches are urgently needed to achieve parity in health outcomes in HIV-infected drug users...
- Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication
Frederick L Altice
Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
Clin Infect Dis 38:S376-87. 2004
..Moreover, DAART should incorporate enhanced elements such as convenience, flexibility, confidentiality, cues and reminders, responsive pharmacy and medical services, and specialized training for staff...
- HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications
R Douglas Bruce
Yale University AIDS Program, New Haven, CT 06510 2283, United States
Int J Drug Policy 18:326-8. 2007
..Until buprenorphine maintenance therapy (BMT) was introduced, few effective strategies aimed at achieving reduction in illicit drug use were available as a conduit to anti-retroviral therapy (ARV) among IDUs...
- Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial
Duncan Smith Rohrberg Maru
Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, USA
J Acquir Immune Defic Syndr 50:176-81. 2009
....
- Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication
R Douglas Bruce
Yale University AIDS Program, New Haven, CT 06510, USA
Am J Drug Alcohol Abuse 38:206-12. 2012
....
- Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment
SANDRA ANN SPRINGER
Yale AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510, USA
J Urban Health 87:592-602. 2010
..Future randomized controlled trials are needed to affirm its benefit in this highly vulnerable population...
- Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users
Duncan Smith-Rohrberg
Yale University AIDS Program, New Haven, Connecticut 06510-2283, USA
J Acquir Immune Defic Syndr 43:S48-53. 2006
..These results suggest the potential utility of integrating these services into DAART interventions (DAART-Plus) targeting HIV-infected drug users with problematic adherence...
- Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
Frederick L Altice
Yale University AIDS Program, New Haven, Connecticut 06510, USA
J Urban Health 80:416-27. 2003
..In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention...
- Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention
Chethan Bachireddy
Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT 06510, USA
Drug Alcohol Depend 116:151-7. 2011
..Pre-incarceration HIV transmission behaviors and current attitudes toward opioid substitution therapy (OST) among HIV-infected male prisoners in Malaysia have important implications for secondary HIV prevention efforts...
- Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
R Douglas Bruce
Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT, United States
Drug Alcohol Depend 105:234-9. 2009
..BUP/NLX and TPV/r should therefore be used cautiously to avoid decreased efficacy of TPV in patients taking these agents concomitantly...
- Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial
Duncan Smith Rohrberg Maru
Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
J Acquir Immune Defic Syndr 46:555-63. 2007
..Directly administered antiretroviral therapy (DAART) is an effective intervention that improves clinical outcomes among HIV-infected drug users. Its effects on antiretroviral drug resistance, however, are unknown...
- Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone
David A Fiellin
Departments of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520 8093, USA
J Acquir Immune Defic Syndr 56:S33-8. 2011
..Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment...
- HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study
Frederick L Altice
Yale University School of Medicine, New Haven, CT, USA
J Acquir Immune Defic Syndr 56:S22-32. 2011
..Having opioid dependence and HIV infection are associated with poor HIV-related treatment outcomes...
- Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations
Duncan Smith Rohrberg Maru
Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA
Clin Infect Dis 47:952-61. 2008
..Data are lacking on outcomes of treatment with pegylated interferon plus ribavirin (PEG-RBV) in correctional settings...
- Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community
Sandra A Springer
Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut 06510-2283, USA
Clin Infect Dis 38:1754-60. 2004
..More effective community-release programs are needed for incarcerated patients with HIV disease...
- Substance abuse, violence, and HIV in women: a literature review of the syndemic
Jaimie P Meyer
Yale University School of Medicine, AIDS Program, New Haven, CT 06510 2283, USA
J Womens Health (Larchmt) 20:991-1006. 2011
..Development and adaptation of evidence-based interventions that incorporate prevention of violence and management of victimization to target this vulnerable group of women and thereby promote better health outcomes are urgently needed...
- Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection
Frederick L Altice
Yale University, School of Medecine, New Haven, CT 06510 2283, USA
J Urban Health 82:312-26. 2005
..Alternative methods of facilitating more widespread HIV testing, such as saliva tests, rapid serologic tests, and more routine testing in high HIV-prevalence areas should be considered both for clinical and for public health benefits...
- Public health implications for adequate transitional care for HIV-infected prisoners: five essential components
Sandra A Springer
AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06511, USA
Clin Infect Dis 53:469-79. 2011
....
- Clinical care of the HIV-infected drug user
R Douglas Bruce
Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510, USA
Infect Dis Clin North Am 21:149-79, ix. 2007
....
- Case series of buprenorphine injectors in Kuala Lumpur, Malaysia
R Douglas Bruce
AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
Am J Drug Alcohol Abuse 34:511-7. 2008
..Prospective cohort studies, rather than hospital-derived samples, are needed to better understand the safety of buprenorphine injection...
- Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening
Ryan K Schwarz
Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA
Am J Drug Alcohol Abuse 35:439-44. 2009
..Currently, tuberculin skin testing (TST) is recommended for patients enrolling in methadone maintenance treatment (MMT), but not for those enrolling in buprenorphine maintenance treatment (BMT)...
- Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence
Sanjay Basu
Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06511, USA
J Subst Abuse Treat 32:399-409. 2007
....
- HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners
Sandra A Springer
Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, Suite 323, New Haven, CT 06511, USA
Am J Drug Alcohol Abuse 37:12-21. 2011
....
- Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice
R Douglas Bruce
Yale University AIDS Program, 135 College Street, New Haven, CT 06511, USA
J Acquir Immune Defic Syndr 41:563-72. 2006
..Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur...
- A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization
Marwan M Azar
Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, Suite 323, New Haven 06511, CT, USA
Drug Alcohol Depend 112:178-93. 2010
..Alcohol use disorders (AUDs) are highly prevalent and associated with non-adherence to antiretroviral therapy, decreased health care utilization and poor HIV treatment outcomes among HIV-infected individuals...
- The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention
Frederick L Altice
AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510, USA
Clin Infect Dis 43:S178-83. 2006
..Dialogue among practitioners and policy makers in the HIV care and substance abuse communities will facilitate an effective expansion of buprenorphine and ensure that these beneficial outcomes are achieved...
- Managing HIV/AIDS in correctional settings
Sandra A Springer
Yale University School of Medicine, Yale AIDS Program, Section of Infectious Diseases, 135 College Street, Suite 323, New Haven, CT 06510, USA
Curr HIV/AIDS Rep 2:165-70. 2005
....
- Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services
Laurie Sylla
Yale University AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States
Int J Drug Policy 18:306-12. 2007
....
- Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases
Robert D Bruce
Yale University AIDS Program, New Haven, Connecticut 06511, USA
Am J Drug Alcohol Abuse 33:869-74. 2007
..Previous reports in the literature have suggested hepatotoxicity with buprenorphine tempering initial enthusiasm of the safety of buprenorphine in HCV-infected patients...
- Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model
Margo D Simon
AIDS Program, Yale University School of Medicine, New Haven, CT, USA
AIDS Care 22:462-74. 2010
..Community-based assessments are urgently needed as HAART rollouts continue. Adaptation of this IMB-based survey may better inform efforts to enhance HAART-program implementation in resource-limited settings globally...
- Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications
Shaili Gupta
Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
J Urban Health 86:263-79. 2009
..We present a review of diagnosis, prevention, and the recently streamlined treatment guidelines for management of HBV infection in correctional settings, and discuss the implications and public health impact of these measures...
- Models for integrating buprenorphine therapy into the primary HIV care setting
Sanjay Basu
AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Infect Dis 42:716-21. 2006
..The key barriers against effective integration of buprenorphine maintenance therapy and primary HIV services are discussed, and we suggest several mechanisms to overcome such obstacles...
- Observations on implementing routine HIV testing in jails
Ravi Kavasery
Yale University School of Medicine, Yale University AIDS Program, New Haven, Connecticut 06510-2283, USA
AIDS Patient Care STDS 21:715-6; author reply 717. 2007
- A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs
Meredith Camp Binford
Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
Curr HIV/AIDS Rep 9:287-312. 2012
..Future research directions, including the development of interventions that promote long-term improvements in adherence and virologic outcomes, are discussed...
- Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
Ali S Saber-Tehrani
Yale University AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT 06510, USA
Am J Drug Alcohol Abuse 37:1-11. 2011
..When medication-assisted treatment for opioid dependence is concurrently used with psychotropic medications, problematic pharmacokinetic drug interactions may occur...
- Attitudes toward and beliefs about prenatal HIV testing policies and mandatory HIV testing of newborns among drug users
Odicie Fielder
Yale University School of Medicine, New Haven, Connecticut, USA
AIDS Public Policy J 20:74-91. 2005
..We also examined to what extent negative experiences and stigmatization affected attitudes toward HIV testing...
- Cost-effectiveness of HIV screening for incarcerated pregnant women
Stephen Resch
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510-2283, USA
J Acquir Immune Defic Syndr 38:163-73. 2005
..In settings where HIV screening policies are not in place, however, the implementation of RPS can be expected to significantly reduce pediatric HIV cases and net health care expenditures...
- Neurocognitive impairment and HIV risk factors: a reciprocal relationship
Pria Anand
Department of Medicine, Yale University School of Medicine, New Haven, CT 06510 2283, USA
AIDS Behav 14:1213-26. 2010
..In order to be effective, risk-reduction interventions must therefore take into account the impact of cognitive impairment on learning and behavior...
- Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosis
Sandra A Springer
Yale University AIDS Program, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, 06510 2283, USA
Clin Infect Dis 36:e162-4. 2003
..To date, this is the first presentation of symptomatic hyperlactatemia in a patient with HIV infection and HGE...
- Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence
Ryan Schwarz
Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
J Subst Abuse Treat 43:451-7. 2012
..Overall, ED utilization was 0.93 events per person year and was significantly reduced by BMT, with increasing time (retention) on BMT. BMT had no significant effect on hospitalizations or average length of stay...
- Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study
Robert S Broadhead
Department of Sociology, University of Connecticut, Storrs 06269 2068, USA
Soc Sci Med 55:235-46. 2002
..Innovative mechanisms that harness drug users' peer pressure to promote positive behavioral changes deserve greater study...
- Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach
Duncan Smith-Rohrberg
Clin Infect Dis 43:1221-2; author reply 1222-3. 2006
- The impact of needle exchange-based health services on emergency department use
Harold A Pollack
School of Public Health, University of Michigan, Ann Arbor 48109 2029, USA
J Gen Intern Med 17:341-8. 2002
....
- Editorial comment: why treat three conditions when it is one patient?
R Douglas Bruce
AIDS Read 13:378-9. 2003
- HIV control efforts should directly address incarceration
Duncan Smith-Rohrberg Maru
Lancet Infect Dis 7:568-9. 2007
- Strategies for primary HIV prevention that target behavioral change
Steven A Safren
Fenway Community Health and Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Clin Infect Dis 45:S300-307. 2007
..Objective evidence of reductions in high-risk behavior in these 3 groups, which account for the majority of HIV transmissions in the United States, has critical implications for reducing the overall rate of new HIV infections...
- HIV testing in correctional institutions: evaluating existing strategies, setting new standards
Sanjay Basu
AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, in New Haven, Connecticut, USA
AIDS Public Policy J 20:3-24. 2005
..Jails present added complexities because of their shorter stay with respect to prisons, and testing, treatment, and counseling policies must be adapted to these settings...
- The association between history of violence and HIV risk: a cross-sectional study of HIV-negative incarcerated women in Connecticut
Anita Ravi
Atlanta, GA, USA
Womens Health Issues 17:210-6. 2007
....
- Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir
R Douglas Bruce
AIDS 20:783-4. 2006
